Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury via mitochondrial or other mechanisms

被引:21
|
作者
Rana, Payal [1 ]
Aleo, Michael D. [1 ]
Wen, Xuerong [2 ]
Kogut, Stephen [2 ]
机构
[1] Pfizer, Drug Safety Res & Dev, Groton, CT 06340 USA
[2] Univ Rhode Isl, Coll Pharm, Kingston, RI 02881 USA
关键词
Mitochondrial toxicity; FAERS database; Adverse event reporting; Drug-induced liver injury; Hepatotoxicity; INDUCED LIVER-INJURY; FAERS DATABASE; PUBLIC VERSION; HEPG2; CELLS; IN-VIVO; TOXICITY; DYSFUNCTION; SUSCEPTIBILITY; CYTOTOXICITY; INCREASES;
D O I
10.1016/j.apsb.2021.05.028
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug-induced liver injury (DILI) is a leading reason for preclinical safety attrition and postmarket drug withdrawals. Drug-induced mitochondrial toxicity has been shown to play an essential role in various forms of DILI, especially in idiosyncratic liver injury. This study examined liver injury reports submitted to the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) for drugs associated with hepatotoxicity via mitochondrial mechanisms compared with non-mitochondrial mechanisms of toxicity. The frequency of hepatotoxicity was determined at a group level and individual drug level. A reporting odds ratio (ROR) was calculated as the measure of effect. Between the two DILI groups, reports for DILI involving mitochondrial mechanisms of toxicity had a 1.43 (95% CI 1.42-1.45; P < 0.0001) times higher odds compared to drugs associated with non-mitochondria l mechanisms of toxicity. Antineoplastic, antiviral, analgesic, antibiotic, and antimycobacterial drugs were the top five drug classes with the highest ROR values. Although the top 20 drugs with the highest ROR values included drugs with both mitochondrial and non-mitochondrial injury mechanisms, the top four drugs (ROR values > 18: benzbromarone, troglitazone, isoniazid, rifampin) were associated with mitochondrial mechanisms of toxicity. The major demographic influence for DILI risk was also examined. There was a higher mean patient age among reports for drugs that were associated with mitochondrial mechanisms of toxicity [56.1 +/- 18.33 (SD)] compared to non-mitochondrial mechanisms [48 +/- 19.53 (SD)] (P < 0.0001), suggesting that age may play a role in susceptibility to DILI via mitochondrial mechanisms of toxicity. Univariate logistic regression analysis showed that reports of liver injury were 2.2 (odds ratio: 2.2, 95% CI 2.12-2.26) times more likely to be associated with older patient age, as compared with re-ports involving patients less than 65 years of age. Compared to males, female patients were 37% less likely (odds ratio: 0.63, 95% CI 0.61-0.64) to be subjects of liver injury reports for drugs associated with mitochondrial toxicity mechanisms. Given the higher proportion of severe liver injury reports among drugs associated with mitochondrial mechanisms of toxicity, it is essential to understand if a drug causes mitochondrial toxicity during preclinical drug development when drug design alternatives, more clini-cally relevant animal models, and better clinical biomarkers may provide a better translation of drug -induced mitochondrial toxicity risk assessment from animals to humans. Our findings from this study align with mitochondrial mechanisms of toxicity being an important cause of DILI, and this should be further investigated in real-world studies with robust designs. 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:3857 / 3868
页数:12
相关论文
共 50 条
  • [1] Hepatotoxicity reports in the FDA adverse event reporting system database:A comparison of drugs that cause injury via mitochondrial or other mechanisms
    Payal Rana
    Michael D.Aleo
    Xuerong Wen
    Stephen Kogut
    [J]. Acta Pharmaceutica Sinica B, 2021, 11 (12) : 3857 - 3868
  • [2] Detecting drugs that cause thrombocytopenia: A comparison of published case reports and data mining of the USFDA adverse event reporting system (AERS) database.
    Li, Xiaoning
    Terrell, Deirdra R.
    George, James N.
    Vesely, Sara K.
    [J]. BLOOD, 2006, 108 (11) : 140A - 141A
  • [3] Identification of Generic Drugs in the FDA Adverse Event Reporting System
    Iyer, Geetha S.
    Marimuthu, Sathiya Priya
    Segal, Jodi B.
    Singh, Sonal
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 406 - 407
  • [4] Comparison of adverse reaction reports for rivastigmine, and donepezil using the FDA's Adverse Event Reporting System
    Rizzo, JA
    Chang, SB
    Cohen, A
    [J]. ANNALS OF NEUROLOGY, 2001, 50 (03) : S76 - S76
  • [5] Comparison of adverse reaction reports for rivastigmine and donepezil using the FDA's adverse event reporting system
    Rizzo, J
    Chang, SB
    Ofman, J
    [J]. NEUROBIOLOGY OF AGING, 2002, 23 (01) : S116 - S116
  • [6] Comparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation Antipsychotics
    Evoy, Kirk E.
    Teng, Chengwen
    Encarnacion, Victor G.
    Frescas, Brian
    Hakim, John
    Saklad, Stephen
    Frei, Christopher R.
    [J]. SUBSTANCE ABUSE-RESEARCH AND TREATMENT, 2019, 13
  • [7] DRUGS ASSOCIATED WITH ADVERSE DRUG EVENTS IN CHILDREN: ANALYSIS OF THE UNITED STATES FDA ADVERSE EVENT REPORTING SYSTEM DATABASE
    Lee, W. J.
    Schumock, G. T.
    Lee, T. A.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A70 - A70
  • [8] An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System
    Iyer, Geetha
    Marimuthu, Sathiya Priya
    Segal, Jodi B.
    Singh, Sonal
    [J]. DRUG SAFETY, 2017, 40 (09) : 799 - 808
  • [9] An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System
    Geetha Iyer
    Sathiya Priya Marimuthu
    Jodi B. Segal
    Sonal Singh
    [J]. Drug Safety, 2017, 40 : 799 - 808
  • [10] Evaluation of spontaneous adverse event reports for kidney injury attributed to atezolizumab within the FDA adverse events reporting system
    Zaafan, Ola
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 460 - 460